Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Wilms Tumor 1Urinary Bladder Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Histiocytosis, Langerhans-Cell 1Hepatoblastoma 1Glioma 1Ependymoma 1

Interventions

Filgrastim 7X-Rays 6Phantoms, Imaging 6Magnetic Resonance Spectroscopy 6Granulocyte Colony-Stimulating Factor 6Specimen Handling 5Nuclear Medicine Department, Hospital 5Carboplatin 5Temozolomide 4Melphalan 4Ifosfamide 4Etoposide 4Busulfan 4Biopsy 4Thiotepa 3Peripheral Blood Stem Cell Transplantation 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2olaparib 2larotrectinib 2ivosidenib 2etoposide phosphate 2erdafitinib 2ensartinib 2Thalidomide 2Paclitaxel 2Mesna 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Medulloblastoma × Pharmacogenomic Variants × Genitourinary × Clear all
NCT03698994 2026-05-27

Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
20 enrolled 9 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡